Schwannomas are benign encapsulated tumors of Schwann cells, the main peripheral glia cells that do not invade the nerve, but rather grow around it. It is extremely rare for a schwannoma to transform and become malignant ([@R1],[@R2]). The majority of schwannomas arise spontaneously and only 4% are associated with neurofibromatosis type 2 (NF2). Sporadic schwannomas represent 6%-8% of all intracranial tumors. Additionally, schwannomas make up to 90% of tumors that occur in the cerebellopontine angle ([@R3]). During the last decade, great progress has been made in the determination of molecular and genetic characteristics causative of both sporadic and familial forms of schwannomas.

Schwannomas are a principal feature of two hereditary tumor diseases, NF2 and schwannomatosis. NF2 is an autosomal dominant disorder caused by germline mutations in the *NF2* gene on 22q12. The population-based birth incidence of NF2 was estimated as 1 case in 33 000-40 000 individuals ([@R4],[@R5]). Approximately 50% of NF2 cases harbor mutations *de novo*, which cannot be identified in any other family members, and this suggests a high mutation rate for this gene ([@R1],[@R3]). The hallmark of this disorder is the clinical finding of bilateral schwannomas involving the eighth cranial nerve (vestibular schwannomas) ([@R6],[@R7]). Schwannomas also occur spontaneously, ie, sporadically. An annual incidence of sporadic vestibular schwannoma was approximately 1.3 per 100 000 ([@R8]). A population-based study in Denmark showed an estimated incidence of 11.5 cases per million inhabitants per year ([@R9]), while the US national tumor registry reported 1.1 cases per 100 000 people per year. Loss of heterozygosity, ie, gross deletion of the *NF2* gene is a common feature found in the majority of sporadic schwannomas. At present, it seems that all sporadic schwannomas are caused by some kind of alteration of *NF2* gene ([@R10]). The majority of detected deletions and mutations result in a truncated (shorter) protein products ([@R11]). The evidence very strongly suggests that all schwannomas are caused by changes in both gene copies and the consequent loss of NF2 protein function ([@R12]).

The main reason why we propose studying *NF2* gene in schwannomas is because there are still many unsolved and inadequately explained issues regarding the full genetic profile of human schwannomas. Today, it is recognized that alterations of the *NF2* gene are a causative event in the tumorigenesis of schwannomas. Therefore, identification of gross deletions of *NF2* gene in a set of patients from Croatia (the first time on a southeastern European population) can contribute to our knowledge of the total frequency of *NF2* alterations and thus improve our understanding of this tumor's etiology.

Materials and methods
=====================

Tumor specimen
--------------

Samples of 20 schwannomas, together with autologous blood samples, were collected from the Department of Neurosurgery and Department of Pathology, Sestre Milosrdnice University Hospital, Zagreb, Croatia. The patients were without clinical NF1, NF2, or Schwannomatosis and had no family history of brain tumors. The schwannoma tissues were frozen in liquid nitrogen and transported to the laboratory, where they were immediately transferred at -75°C. The peripheral blood samples were collected in ethylenediaminetetraacetic acid (EDTA) and processed immediately.

Magnetic resonance imaging (MRI) revealed that the majority of schwannomas were intracranial, while two were located in the spinal nerves. During the operative procedure, the schwannomas were removed using a microneurosurgical technique. They were studied and classified according to WHO criteria by pathologists. Our study was approved by the ethics committees of Medical School University of Zagreb and Sestre Milosrdnice University Hospital, and the patients gave their informed consent.

DNA extraction
--------------

Approximately 0.5 g of tumor tissue was homogenized with 1 mL extraction buffer (10 mM Tris HCl, pH 8.0; 0.1 M EDTA, pH 8.0; 0.5% sodium dodecyl sulfate) and incubated with proteinase K (100 μg/mL; Sigma, St. Louis, MO, USA; overnight at 37°C). Phenol chloroform extraction and ethanol precipitation followed.

Blood was used to extract leukocyte DNA. Five milliliters of blood was lysed with 7 mL distilled water and centrifuged (15-minute/5000 g). The pellet was processed as for DNA extraction from the tissue samples.

Polymerase chain reaction
-------------------------

Two polymorphic regions, D22S444 and D22S929, of the *NF2* gene were studied. In a total volume of 25 μL, two polymorphic markers were amplified by using 5 pmol of each primer ([Table 1](#T1){ref-type="table"}), 200 ng DNA, 2.5 μL 10X buffer II (500 mM KCl, 100 mM Tris-HCl, pH 8.3), 1.5 mM MgCl~2~, 2.5 mM of each dNTP, 0.2 μL (1U) of *Taq* polymerase (Promega, Madison, WI, USA). PCR conditions: initial denaturation, 10 minutes/95°C; denaturation, 30 seconds/95°C; annealing, 30 seconds/55°C; extension, 30 seconds/72°C; final extension, 72°C/10 minutes; 35 cycles. All PCR products were analyzed on 2% agarose gels.

###### 

Primers used for the amplification of microsatellite markers for the *NF2* gene

            Marker              Primers (5′→ 3′)
  ------------------- ------------------------------------------------------------------
            D22S929             CTGCAGATCACAAACTCCTTG           GCATTTATGGAGTATCCACAG
            D22S444             TTTGAACTAAGCCTTAAAAATGC           TGTTTGGCTTGAAGAAGGAG

Loss of heterozygosity
----------------------

To assess LOH of the *NF2*gene, markers D22S444 ([@R13],[@R14]) and D22S929 ([@R15],[@R16]) were chosen from the literature and professional gene databases (EntrezGene *<http://www.ncbi.nlm.nih.gov/>*). Heterozygous samples were visualized on Spreadex EL 400 gels (Elchrom Scientific, Cham, Switzerland), stained with SyberGold (Molecular Probes, Leiden, The Netherlands) and on 15% polyacrylamide gels, stained with silver. Absence or a significant decrease in the intensity of one of the D22S444 and D22S929 alleles in tumor, as compared with the autologous blood sample, was considered as LOH of *NF2* gene.

Results
=======

Schwannomas were classified as WHO grade I and specified as Antoni A or Antoni B ([@R17]) patterns ([Figure 1 A and B](#F1){ref-type="fig"}). Seven (35%) were Antoni A, 9 (45%) were Antoni B, and 4 (20%) had mixed Antoni A and Antoni B features.

![Vestibular schwannoma, (**A**) Antoni A. Tumors were composed of compact spindle cells that had twisted nuclei and indistinct cytoplasmic borders. They were arranged in short bundles. Nuclear palisading and Verocay bodies were present. (**B**) Antoni B. The tumor was composed of loosely arranged Schwann cells admixed with foamy macrophages. In some tumor cells degenerative nuclear changes were seen but mitotic activity was not observed (200 × , hematoxylin and eosin).](CroatMedJ_53_0321-F1){#F1}

Our data set consisted of 20 patients, 15 female. The age of the patients ranged from 12 to 67 years (mean age 50.95; median 52.50). The mean age at diagnosis was 33 years for men and 57 years for women. Their symptoms lasted between 2 to 72 months (mean 38.95; median 42.0).

The localization of the tumor was as follows: 11 were left vestibular (50%) ([Figure 2](#F2){ref-type="fig"}), 6 were right vestibular (25%), one was found in the right temporal region (IX nerve), while two were found in the left spinal LI and LII nerves. Intracranial schwannomas were predominantly found in women.

![Magnetic resonance image showing lesion in the left pontocerebellar angle.](CroatMedJ_53_0321-F2){#F2}

Of 20 schwannoma samples, 16 were informative when analyzed with both NF2 gene markers (80%). Eleven (55%) were informative for D22S444 and 14 (70%) for D22S929 microsatellite marker. The results regarding *NF2* gene showed 7 out of 16 heterozygous patients with allelic losses (43.75%). This is the total number of changes analyzed by both microsatellite markers. When specifying changes to distinct gene regions, there were 5 LOHs discovered with D22S444 (45.5%) and 2 LOHs discovered with D22S929 (14.3%). The LOHs were lost for one marker and not the other. D22S929 is an intragenic marker in intron 1 of the *NF2* gene, so our results showed that in patients heterozygous for D22S929 with loss of the distal marker D22S444 the deletion would start somewhere downstream of the first exons.

LOHs of the *NF2* gene, revealed by both markers, are shown in [Figure 3A](#F3){ref-type="fig"} (D22S444) and B (D22S929).

![Losses of heterozigosity (LOHs) of the *NF2* gene in schwannomas. (**A**) Lanes 1, 3, 6 -- samples demonstrating LOH at D22S444; lanes 2, 4, 5 --corresponding blood samples; lanes 7, 8 -- uninformative patient. (**B**) Lane 1 --100 bp DNA standard; lanes 5, 7, 11 --samples demonstrating LOH at D22S929; lanes 4, 6, 10 -- corresponding blood samples; lanes 2, 3 -- heterozygous patient without LOH; lanes 8, 9 -- uninformative patient.](CroatMedJ_53_0321-F3){#F3}

When assigning the gross deletions of the *NF2* gene to a specific pathohistological classification, the distribution of LOHs was as follows: 4 LOHs were found in Antoni B tumors (57%), 2 in Antoni A (29%), and 1 in Antoni A and B tumors (14%). The pathohistologic diagnosis of the analyzed samples, along with the LOH of the *NF2* gene and polymorphic status of both microsatellite markers is shown in [Table 2](#T2){ref-type="table"}.

###### 

The analyzed samples, loss of heterozygosity of the *NF2* gene, and polymorphic status of D22S444 and D22S929 markers

            Patient No.             Localization               Antoni             D22S444                 D22S929                 Symptoms/           months             Sex             Age
  ----------------------- -------------------------- ------------------ ----------------------- ----------------------- -------------------------------------- --------------- ---------------
           1                       VIII\* left                B                  Heterozygous            Heterozygous             72                                     F               64
           2                       Spinal LII left            A                  Homozygous              Homozygous               3                                      M               40
           3                       VIII right                 B                  LOH                     Homozygous               42                                     F               50
           4                       VIII left                  A                  Homozygous              Homozygous               5                                      F               53
           5                       VIII right                 B                  Homozygous              Homozygous               36                                     F               62
           6                       VIII left                  B                  Heterozygous            LOH                      24                                     F               33
           7                       VIII left                  B                  LOH                     Heterozygous             54                                     F               51
           8                       VIII left                  A                  Homozygous              LOH                      66                                     M               26
           9                       VIII right                 A                  LOH                     Homozygous               42                                     M               12
           10                      VIII right                 B                  Homozygous              Heterozygous             36                                     F               63
           11                      IX right                   A                  Homozygous              Homozygous               36                                     F               59
           12                      VIII left                  A + B              Homozygous              Heterozygous             30                                     F               52
           13                      VIII left                  B                  LOH                     Heterozygous             60                                     F               67
           14                      VIII right                 B                  Homozygous              Heterozygous             54                                     F               51
           15                      VIII left                  B                  Heterozygous            Heterozygous             66                                     F               67
           16                      VIII left                  A+B                Heterozygous            Heterozygous             48                                     F               67
           17                      Spinal LI left             A                  Heterozygous            Heterozygous             2                                      F               49
           18                      VIII left                  A+B                LOH                     Heterozygous             48                                     M               60
           19                      VIII left                  A                  Heterozygous            Heterozygous             48                                     M               27
           20                      VIII right                 A+B                Homozygous              Heterozygous             7                                      F               66

\*VIII = eighth cranial nerve in the cerebellopontine angle (vestibular cranial schwannoma).

Discussion
==========

Our analysis using two microsatellite markers found 43.75% samples with gross deletions of the *NF2* gene. We have already mentioned that gross deletions of the *NF2* gene are frequent events in the molecular pathology of sporadic schwannoma ([@R11]). Although it is well known that the main cause for transformation of the Schwann cells into schwannomas is the inactivation of the *NF2* gene, and the consecutive loss of its protein merlin, the intracellular mechanism of this transformation still needs to be elucidated. It seems that the inactivation of the second allele often occurs via a large deletion of the 22q chromosomal region.

The investigated marker D22S929 is an intragenic marker located within the 32.2-kb-long intron 1 of the *NF2* gene ([@R15],[@R16]). It is a dinucleotide repeat ([@R15]) with reported heterozygosity of 83%, while our sample showed the heterozygosity of 70%. The genetic alterations were found in the *NF2*\'s intron, indicating intragenetic target of this deletion. The marker D22S444 is a tetranucleotide repeat proximal to the *NF2* gene, with reported informativity of 79% ([@R18]). The rates of allelic loss were different between the markers used. This variability of LOHs found in those two genetic regions could indicate more precisely the position of the deleted part and the size this deletion encompasses in our cases. The variability of the results obtained by different microsatellite markers can also elucidate the involvement of genomic instability regarding DNA replication and postreplication repair.

This type of analysis has never previously been performed on a cohort of patients from Croatia, and we believe that our results could broaden the overall *NF2* mutational spectrum. Our results are in accordance with the frequency of LOHs in sporadic schwannomas reported by other authors ([@R19],[@R20]). In other studies, the frequency of LOHs in schwannomas was from 40%-80% -- a fairly large range -- which depended on the number of genetic markers used and the number of cases examined ([@R19]-[@R26]). An incidence of 42.6% of LOHs assessed by 4 microsatellite markers, a number that is very similar to our result, was reported in the study by Bian et al ([@R19]). Moreover, the same study reported difference in *NF2* LOHs between vestibular and spinal schwannomas and the association of higher proliferative index to the schwannomas showing LOH. Hadfield et al ([@R20]) reported LOH occurrence in 54 out of 96 (56%) sporadic vestibular schwannomas, a frequency that while clearly higher is not significant (χ^2^ = 0.433). There are reports of even higher frequencies of losses ([@R22]), which detected 72% of *NF2* deletions by direct sequencing and 77% of LOHs ([@R23]). Vestibular schwannomas were also analyzed by comparative genomic hybridization in several studies. Loss on 22q was reported in 23% of sporadic schwannomas ([@R24]), in which case it was slightly more common in tumors associated to NF2 than those found in sporadic cases, but this difference was not significant. Moreover, Warren et al ([@R25]) examined 66 sporadic vestibular schwannomas and found 23.7% of losses; while Koutsimpelas et al ([@R26]) found losses on the chromosome 22 in 30% of the cases. Mantripragada et al ([@R21]) performed a high resolution study using an array covering 1/3 of human chromosome 22 and found LOH in 45% of schwannomas. An important feature common to all of these analyses is the relatively small number of cases. As systematized in a meta-analysis of 12 years of studying of the mutational spectrum of *NF2* gene ([@R8]), it is obvious that the overall number of investigated sporadic cases remains rather small. Our sample therefore represents approximately 8% of the total worldwide sample size, and is the first that is derived from southeastern Europe.

Loss of expression of NF2 protein product merlin is a universal finding in all schwannomas examined, indicating inactivation of both NF2 alleles. The loss of immunoreactivity was reported in many studies ([@R23],[@R24],[@R27]). The main characteristic of cells lacking NF2 protein product is the loss of contact inhibition of proliferation ([@R28]). Associated with the loss of contact inhibition, merlin-lacking cells are also known to contain defective adherens junctions ([@R29]). Thus, it is understandable that cells that suffered merlin loss show deregulated adhesion to extracellular matrix, which is also shown in schwannoma cells. Furthermore, merlin seems to be directly involved in cytoskeletal organization relevant to myelination ([@R30]). Recent research on *NF2* gene has demonstrated that merlin is a tumor suppressor capable of modulating a wide range of signaling pathways that influence cell growth, motility, and apoptosis ([@R30]). It is clear that merlin is involved in different signal transduction pathways, Hippo and Ras/Raf/Mek pathways being the best characterized, while the latest reports also suggest merlin's connection to the wnt signaling pathway ([@R31],[@R32]). It has been shown that merlin's inactivation is involved in about half of sporadic meningiomas, too. In our previous investigation on meningiomas, two LOHs of the *NF2*gene were found with the D22S929 marker ([@R33]).

When assigning the gross deletions of the *NF2* gene to a specific pathohistological classification, in our study the distribution of LOHs was not associated to any particular morphology. As schwannomas are benign tumors that respond poorly to classical chemotherapeutics and often result in morbidity, the current therapies of choice are surgery and radiosurgery, but it is equally important to develop novel therapeutic approaches. In this context, understanding how merlin's loss causes tumorigenesis would in all likelihood open the door for new therapies. As intracranial schwannomas are relatively rare, our sample represents a valuable asset to the analysis of *NF2* gross deletions in intracranial sporadic cases.

In conclusion, the frequency of NF2 allelic losses observed in Croatian patients is broadly similar to that reported in other populations and thus both confirms the existing hypothesis regarding the tumorigenesis of schwannomas, and contributes to schwannoma genetic profile, helping us to better understand its etiology and treatment.
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